Bayer 1Q earnings rose – Short term trend bullish

Bayer, the German pharmaceutical and life sciences company, reported that 1Q net income rose 20.0% on year to 1.49 billion euros.

Trader 3

Bayer, the German pharmaceutical and life sciences company, reported that 1Q net income rose 20.0% on year to 1.49 billion euros and adjusted EBITDA grew 10.2% to 4.39 billion euros on revenue of 12.85 billion euros, up 4.8% (+6.0% on a currency and portfolio adjusted basis). The company added: "Bayer anticipates that, following the positive start to the year, COVID-19 will continue to impact its business over the course of 2020. It will not be possible to reliably assess the positive and negative effects until later in the year."

From a technical perspective, the stock price remains in a short term up trend within a bullish channel. Prices have broken above the declining 50-day simple moving average thanks to a bullish gap. The daily Relative Strength Index (RSI, 14) is bullish and not overbought. The bias remains bullish as long as 55.6E is support. Next resistance thresholds are set at 64E and 68E. 

Alternatively, a break below 55.6E would call for a reversal down trend with 50 as target.

Source: GAIN Capital, TradingView

Build your confidence risk free
Join our live webinars for the latest analysis and trading ideas. Register now

StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.